Limits...
Expression of the microtubule-associated protein MAP9/ASAP and its partners AURKA and PLK1 in colorectal and breast cancers.

Rouquier S, Pillaire MJ, Cazaux C, Giorgi D - Dis. Markers (2014)

Bottom Line: Results.Expression of MAP9 is downregulated in colorectal cancer compared to normal tissues (P > 10(-3)), whereas those of AURKA and PLK1 are upregulated (P > 10(-4)).MAP9 downregulation is associated with colorectal malignancy and could be used as a disease marker and a new drug target, while AURKA and PLK1 are upregulated.

View Article: PubMed Central - PubMed

Affiliation: Institute of Human Genetics, UPR 1142, CNRS, 141 rue de la Cardonille, 34396 Montpellier, France.

ABSTRACT

Background: Colorectal and breast cancers are among the most common cancers worldwide. They result from a conjugated deficiency of gene maintenance and cell cycle control.

Objective: We investigate the expression of the microtubule-associated protein MAP9/ASAP and its two partners AURKA and PLK1 in colorectal tumors as well as in ductal breast cancers.

Materials and methods: 26 colorectal cancer samples and adjacent normal tissues and 77 ductal breast cancer samples from grade I to grade III were collected. Real-time quantitative PCR was used to analyse the expression of MAP9, AURKA, and PLK1. Results. Expression of MAP9 is downregulated in colorectal cancer compared to normal tissues (P > 10(-3)), whereas those of AURKA and PLK1 are upregulated (P > 10(-4)). In ductal breast cancer, we found a grade-dependent increase of AURKA expression (P > 10(-3)), while the variations of expression of MAP9 and PLK1 are not significant (P > 0.2).

Conclusions: MAP9 downregulation is associated with colorectal malignancy and could be used as a disease marker and a new drug target, while AURKA and PLK1 are upregulated. In ductal breast cancer, AURKA overexpression is strongly associated with the tumor grade and is therefore of prognostic value for the progression of the disease.

Show MeSH

Related in: MedlinePlus

MAP9, AURKA, and PLK1 mRNA levels in ductal breast cancer. The mRNA levels were measured by real-time PCR from RT-PCR reactions of 77 ductal breast tumors. Individual values were normalized to two control genes. Gene expression of MAP9, AURKA, and PLK1 was evaluated by comparing the arithmetic means of the samples belonging to each of the 3 tumor grades SBRI (n = 5), SBRII (n = 28), and SBRIII (n = 44). For MAP9 and PLK1, the differences between the 3 tumor stages were not statistically significant (n.s.), whereas for AURKA there is an increase of gene expression from stage I to III (*P < 0.005, **P < 0.0001). The ratio of gene expression between the 3 tumors stages is indicated in the inset.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4022107&req=5

fig2: MAP9, AURKA, and PLK1 mRNA levels in ductal breast cancer. The mRNA levels were measured by real-time PCR from RT-PCR reactions of 77 ductal breast tumors. Individual values were normalized to two control genes. Gene expression of MAP9, AURKA, and PLK1 was evaluated by comparing the arithmetic means of the samples belonging to each of the 3 tumor grades SBRI (n = 5), SBRII (n = 28), and SBRIII (n = 44). For MAP9 and PLK1, the differences between the 3 tumor stages were not statistically significant (n.s.), whereas for AURKA there is an increase of gene expression from stage I to III (*P < 0.005, **P < 0.0001). The ratio of gene expression between the 3 tumors stages is indicated in the inset.

Mentions: Tumor samples were histologically graded SBRI to III as reflecting the severity of the disease (Scarff Bloom Richardson (SBR) grade) [15, 29, 30]. Since coupled normal biopsies are not available in breast cancers, we compared here the 3 tumor stages to each other to investigate whether gene expression could be correlated with the severity of the disease, rather than to compare gene expression in tumors with that of unrelated normal breast samples. As shown in Figure 2, expression of MAP9 and PLK1 remains stable whatever the stage is, whereas the expression of AURKA clearly increased from grade I to III (from 1 to 2.2, inset Figure 2, P < 0.001). We then confirmed that AURKA expression is enhanced in ductal breast tumors and is a valuable marker of the evolution of the disease.


Expression of the microtubule-associated protein MAP9/ASAP and its partners AURKA and PLK1 in colorectal and breast cancers.

Rouquier S, Pillaire MJ, Cazaux C, Giorgi D - Dis. Markers (2014)

MAP9, AURKA, and PLK1 mRNA levels in ductal breast cancer. The mRNA levels were measured by real-time PCR from RT-PCR reactions of 77 ductal breast tumors. Individual values were normalized to two control genes. Gene expression of MAP9, AURKA, and PLK1 was evaluated by comparing the arithmetic means of the samples belonging to each of the 3 tumor grades SBRI (n = 5), SBRII (n = 28), and SBRIII (n = 44). For MAP9 and PLK1, the differences between the 3 tumor stages were not statistically significant (n.s.), whereas for AURKA there is an increase of gene expression from stage I to III (*P < 0.005, **P < 0.0001). The ratio of gene expression between the 3 tumors stages is indicated in the inset.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4022107&req=5

fig2: MAP9, AURKA, and PLK1 mRNA levels in ductal breast cancer. The mRNA levels were measured by real-time PCR from RT-PCR reactions of 77 ductal breast tumors. Individual values were normalized to two control genes. Gene expression of MAP9, AURKA, and PLK1 was evaluated by comparing the arithmetic means of the samples belonging to each of the 3 tumor grades SBRI (n = 5), SBRII (n = 28), and SBRIII (n = 44). For MAP9 and PLK1, the differences between the 3 tumor stages were not statistically significant (n.s.), whereas for AURKA there is an increase of gene expression from stage I to III (*P < 0.005, **P < 0.0001). The ratio of gene expression between the 3 tumors stages is indicated in the inset.
Mentions: Tumor samples were histologically graded SBRI to III as reflecting the severity of the disease (Scarff Bloom Richardson (SBR) grade) [15, 29, 30]. Since coupled normal biopsies are not available in breast cancers, we compared here the 3 tumor stages to each other to investigate whether gene expression could be correlated with the severity of the disease, rather than to compare gene expression in tumors with that of unrelated normal breast samples. As shown in Figure 2, expression of MAP9 and PLK1 remains stable whatever the stage is, whereas the expression of AURKA clearly increased from grade I to III (from 1 to 2.2, inset Figure 2, P < 0.001). We then confirmed that AURKA expression is enhanced in ductal breast tumors and is a valuable marker of the evolution of the disease.

Bottom Line: Results.Expression of MAP9 is downregulated in colorectal cancer compared to normal tissues (P > 10(-3)), whereas those of AURKA and PLK1 are upregulated (P > 10(-4)).MAP9 downregulation is associated with colorectal malignancy and could be used as a disease marker and a new drug target, while AURKA and PLK1 are upregulated.

View Article: PubMed Central - PubMed

Affiliation: Institute of Human Genetics, UPR 1142, CNRS, 141 rue de la Cardonille, 34396 Montpellier, France.

ABSTRACT

Background: Colorectal and breast cancers are among the most common cancers worldwide. They result from a conjugated deficiency of gene maintenance and cell cycle control.

Objective: We investigate the expression of the microtubule-associated protein MAP9/ASAP and its two partners AURKA and PLK1 in colorectal tumors as well as in ductal breast cancers.

Materials and methods: 26 colorectal cancer samples and adjacent normal tissues and 77 ductal breast cancer samples from grade I to grade III were collected. Real-time quantitative PCR was used to analyse the expression of MAP9, AURKA, and PLK1. Results. Expression of MAP9 is downregulated in colorectal cancer compared to normal tissues (P > 10(-3)), whereas those of AURKA and PLK1 are upregulated (P > 10(-4)). In ductal breast cancer, we found a grade-dependent increase of AURKA expression (P > 10(-3)), while the variations of expression of MAP9 and PLK1 are not significant (P > 0.2).

Conclusions: MAP9 downregulation is associated with colorectal malignancy and could be used as a disease marker and a new drug target, while AURKA and PLK1 are upregulated. In ductal breast cancer, AURKA overexpression is strongly associated with the tumor grade and is therefore of prognostic value for the progression of the disease.

Show MeSH
Related in: MedlinePlus